Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice.

Autor: Deppas JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Clump DA; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., D'Argenio DZ; Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA., Bakkenist CJ; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Aug; Vol. 94 (2), pp. 271-283. Date of Electronic Publication: 2024 May 14.

Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS.

Autor: Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Krishnamurthy A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Gore S; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Publikováno v: Biomedical chromatography : BMC [Biomed Chromatogr] 2022 Nov; Vol. 36 (11), pp. e5455. Date of Electronic Publication: 2022 Aug 08.

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.

Autor: Manzo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Puhalla S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pahuja S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Ding F; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lin Y; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Appleman L; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Tawbi H; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Stoller R; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Lee JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Diergaarde B; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA., Yu J; Department of Pathology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, USA., Tan AR; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Levine Cancer Institute, Charlotte, NC, USA., Belani CP; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA., Chew H; Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA., Garcia AA; Department of Medicine, Louisiana State University, New Orleans, LA, USA., Morgan RJ; Department of Molecular Pharmacology, City of Hope Beckman Research Institute, Duarte, CA, USA., Wahner Hendrickson AE; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Visscher DW; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Hurley RM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Swisher EM; Department of Obstetrics and Gynecologic, University of Washington, Seattle, WA, USA., Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Katz T; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Ji J; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zhang Y; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chen A; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Duan W; Department of Human and Molecular Genetics, The Florida International University, Miami, FL, USA., Giranda V; AbbVie Laboratories, North Chicago, IL, USA., Shepherd SP; AbbVie Laboratories, North Chicago, IL, USA., Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA. beumerj@gmail.com.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 May; Vol. 89 (5), pp. 721-735. Date of Electronic Publication: 2022 Apr 18.

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.

Autor: Tan AR; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Antoinette.Tan@atriumhealth.org.; Atrium Health, Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA. Antoinette.Tan@atriumhealth.org., Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kiesel BF; University of Pittsburgh, Pittsburgh, PA, USA., Stein MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Columbia University Medical Center, New York, NY, USA., Moss RA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Bristol-Myers Squibb, Lawrenceville, NJ, USA., Malhotra J; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Aisner J; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Shah M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Gounder M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lin H; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kane MP; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lin Y; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Ji J; Frederick National Lab for Cancer Research, Bethesda, MD, USA., Chen A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Beumer JH; University of Pittsburgh, Pittsburgh, PA, USA., Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; New York University Langone Health's Perlmutter Cancer Center, New York, NY, USA.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jan; Vol. 89 (1), pp. 49-58. Date of Electronic Publication: 2021 Oct 20.

In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.

Autor: Joshi A; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA., Kiesel BF; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Chaphekar N; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA., Jones R; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Kunos CA; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Taylor S; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, USA., Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Venkataramanan R; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA. rv@pitt.edu.; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15261, USA. rv@pitt.edu., Beumer JH; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA. beumerj@gmail.com.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beumerj@gmail.com.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Nov; Vol. 86 (5), pp. 633-640. Date of Electronic Publication: 2020 Sep 28.